Cerebrolysin — the leaflet in plain English: dosage, dilution, administration

If you have landed here with a prescription in your hand or an ampoule on the table, the leaflet helps you less than it should — it is written for the doctor. This article translates the part that matters for someone about to start the treatment.

For context — what the substance is, what indications it has and what independent studies show — read the complete guide to Cerebrolysin first. Here we deal strictly with administration.

The concentration does not change. Only the ampoule does.

The most common confusion: people search for a “more concentrated Cerebrolysin”. It does not exist. The concentration is fixed at 215.2 mg of concentrate per millilitre, in every ampoule size. What changes is the total amount.

The rest of the solution is sodium hydroxide and water for injections.

Which dose, for which indication

The doses on the leaflet differ according to the reason it is being given:

• organic and neurodegenerative brain disorders — 5–30 ml a day;
• complications after a stroke — 10–50 ml a day;
• traumatic brain injury — 10–50 ml a day.

Note the ranges: they are wide, and choosing within them is not a matter of preference. The doctor sets it, according to the diagnosis, age and kidney status.

The golden rule: above 10 ml, infusion only

This is where mistakes are made most often, and the mistake is not cosmetic.

• up to 5 ml — may be given intramuscularly;
• up to 10 ml — may be given intravenously, slowly;
• 10–50 ml — only by infusion, diluted.

It is diluted to a total volume of about 250 ml, in saline, Ringer's solution or 5% glucose, and the infusion runs over 15–60 minutes.

The reason is simple: a large amount of protein hydrolysate pushed quickly into the circulation is exactly the situation in which a hypersensitivity reaction becomes dangerous. Dilution and time are safety measures, not formalities.

What must NOT go in the same bag

Cerebrolysin must not be mixed in an infusion with amino acid solutions. This is an explicit incompatibility on the leaflet, not a general precaution.

The practical rule: if you are also having an amino acid protocol, it is given separately, not through the same line at the same time.

It is not an injection, it is a course

The leaflet describes treatment as a course: daily administration for 10–20 days. A one-off session is not the regimen described in the authorisation — it is one part of a regimen set by the doctor.

If someone offers you “a Cerebrolysin infusion” as a single event, with no diagnosis and no plan, the right question is which indication is being treated.

Contraindications

• hypersensitivity to Cerebrolysin or to the components of the solution;
• epilepsy and status epilepticus;
• severe kidney failure.

The side effects reported on the leaflet are overwhelmingly very rare — fewer than 1 in 10,000 administrations — and include hypersensitivity reactions, headache, nausea, a burning sensation at the injection site, chills. That does not mean they do not exist; it means administration must take place where someone can recognise and treat them.

One nuance we want to flag: the patient leaflet, approved in 2012, refers to severe kidney failure, while the summary of product characteristics published on Mediately, updated in 2016, lists kidney failure among the contraindications, without qualification. In practice, this means kidney function is discussed beforehand, whichever document you go by.

What to tell the doctor before the first administration

The leaflet and the SmPC (summary of product characteristics) name a few situations that need special attention, apart from the contraindications:

• antidepressants or monoamine oxidase inhibitors (MAOIs) — additive side effects may occur; in these cases the SmPC recommends lowering the antidepressant dose, a decision that belongs to the doctor who prescribed it;
• an allergic tendency — “allergic diathesis”, in the leaflet's terms;
• epilepsy or grand mal seizures — the treatment may increase the frequency of seizures;
• pregnancy and breastfeeding — there are no human data; Cerebrolysin is used only after a careful assessment of the balance between risk and benefit.

Vitamins and cardiovascular medicines may be given during the same period, but they are not mixed in the same syringe or bag as Cerebrolysin.

Why the rate of administration matters

Among the rare side effects, the leaflet links several directly to administration that is too fast: dizziness, palpitations and rhythm disturbances, a feeling of warmth and sweating. That explains why the diluted infusion runs over 15–60 minutes and why, with us, it takes 45–60 minutes.

The leaflet also contains an honest note: because the medicine is used a lot in older people, some of the reported reactions are typical of this age group and can occur without treatment. That is why a reaction that appears after an infusion is discussed with the doctor rather than attributed automatically.

What the leaflet says about repeating courses

Besides the 10–20-day course, the leaflet also describes what comes next: after the initial course, the frequency may be reduced to 2–3 administrations a week, and between courses there is a break equal in length to the course. Whether and when a course is repeated is decided by the doctor who set the indication, according to progress.

Packs, storage and the appearance of the solution

In the Medicines Nomenclature of the National Agency for Medicines (ANM, Romania's medicines regulator), updated on 11 September 2026, Cerebrolysin 215.2 mg/ml is listed in four packs — boxes of 10 ampoules of 1 ml and of 5 ampoules each of 5 ml, 10 ml and 20 ml — all dispensed on prescription.

From the SmPC, the storage and handling rules:

• store below 25°C, in the original pack;
• draw the solution from the ampoule only immediately before use, and discard whatever is left — the ampoule is single-use;
• use only a clear, slightly yellowish (amber) solution;
• it is incompatible with solutions that alter pH (the SmPC gives the range 5.0–8.0) and with solutions containing lipids;
• when given through a long-term catheter, the line is flushed with saline before and after.

Overdose and missed doses

The leaflet notes that no harmful effects on health are known following an overdose or poisoning — and the risk is small anyway, because the medicine is given by medical staff. If a day of the course is missed, the next dose is not doubled.

What you will not find on the leaflet

The leaflet says how the medicine is given and for which indications it is authorised. It does not say how well it works compared with placebo, nor what independent reviews have found. For that we have written separately about what the studies show about Cerebrolysin — including the results that do not favour it.

How it is done at Synerva

A single protocol, with no variants: one 10 ml ampoule (2,152 mg), diluted in 250 ml saline, given over 45–60 minutes, only at the clinic, with monitoring throughout. It is given on the basis of a documented neurological diagnosis and after a medical assessment — not on request.

Details and price: Cerebrolysin infusion.

Sources

Cerebrolysin 215.2 mg/ml leaflet (Romanian patient leaflet) — composition, doses, dilution rules, incompatibilities, contraindications.

Summary of product characteristics — Mediately — the same data, in the format for professionals; interactions, pregnancy, storage, incompatibilities (SmPC updated on 1 June 2016).

Nomenclature of medicines for human use — ANM (Romanian medicines regulator) — the authorised packs and dispensing status (version of 11 September 2026).

For information only. Cerebrolysin is a prescription-only medicine; the dose and regimen are set by the doctor, after assessing each case.